Dermavant is developing and commercializing therapeutics for medical dermatology. The skin is the largest organ of the body and millions of people globally suffer with chronic skin conditions. Dermavant is building a dermatology pipeline of product candidates that target specific unmet needs in two of the largest growing immuno-dermatology conditions - plaque psoriasis and atopic dermatitis. VTAMA®, Dermavant’s lead candidate is a topical formulation that is an agonist for the aryl hydrocarbon receptor. Recently, Dermavant announced positive results from their Phase 3 trial of VTAMA® for patients with Atopic Dermatitis.

Dermavant Sciences


						
															
										Page
									
													
						
							
								Case Study
							
							
															
						
					


                         For Healthcare Professionals
                         

                           
                             
                               
                               
                             
                           

                           
                             
                               
                               
                             
                           
                         
                       

The mental and physical effects of psoriasis can take a toll on patients, making it crucial to address all aspects of living with a chronic skin condition to potentially improve overall quality of life. Hear more insights on how to live well with psoriasis in this National Psoriasis Foundation Psound Bytes podcast episode, featuring Dr. Alice Gottlieb: https://bit.ly/3NHlMHd. #WorldPsoriasisDay 

Dermavant’s AD drug not just making up the numbers - The Pharma Letter

Dermavant reports positive late-stage results for Vtama cream in atopic dermatitis - PMLiVE

Vtama Cream From Dermavant Sciences - Pharmacy Times

Organon set to acquire Dermavant in a $1.2 billion deal - Investing.com

Dermavant’s Vtama receives FDA approval for plaque psoriasis - PMLiVE

Dermavant Announces Tapinarof Data Presentation at the Innovations in Dermatology Conference - Business Wire

Compliance Program

Skin deep: Organon buys Dermavant for $1.2B - BioWorld Online

VTAMA Cream

 Dermavant Drug Enters New Phase 

Dermavant out-licenses tapinarof in Japan - The Pharma Letter

Dermavant Announces Two Successful Phase III Plaque Psoriasis Trials - BioSpace

Dermavant Bags GSK Phase III-Ready Psoriasis Treatment in $330 Million Deal - BioSpace

Dermavant Sciences Shaves Weeks Off Its NDA Timeline - Veeva

Dermavant Named One of Fortune® Magazine’s 2020 “100 Best Small and Medium Companies to Work For” - Business Wire

Roivant Sciences Offloads Psoriasis Medicine Maker To Organon For Up To $1.2B - Benzinga


						
															

										Post
									
								Corporate													
						
							
								Dermavant Appoints John Darden as New Head of Marketing
							
							
								– In his previous role, Darden led Otezla® (apremilast) tablet, a leading brand in the competitive psoriasis marketplace – LONG BEACH, Calif., and BASEL, Switzerland, October 5, 2023 – Dermavant Sciences, a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, today announced the appointment of John Darden as Vice President of Marketing. […]
							
						
					

Organon to Acquire Dermavant - citybiz


						
															

										Post
									
								Atopic Dermatitis													
						
							
								Dermavant Reports Positive Topline Results from ADORING 2 Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% Once Daily in Adults and Children as Young as 2 Years Old
							
							
								– 46.4% of subjects receiving VTAMA cream, 1% achieved the primary endpoint of Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-ADTM) response of clear (0) or almost clear (1) with at least a 2-grade improvement from baseline at Week 8, versus 18.0% on vehicle (P<0.0001) – – All secondary endpoints were met with a high […]
							
						
					

Organon Completes Acquisition of Dermavant - njbmagazine.com

 Roivant receives bad news — and so does Softbank 


						
															

										Post
									
								Corporate													
						
							
								Vince Ippolito Appointed as President and COO
							
							
								Former Chief Commercial Officer at Anacor and Medicis joins leadership team Mr. Ippolito has launched over 20 branded medicines in dermatology Dermavant has licensed its fourth investigational drug for the treatment of acne BASEL, Switzerland, September 29, 2017 /PRNewswire/ — Dermavant Sciences, a biopharmaceutical company focused on developing innovative therapies for dermatologic conditions, today announced […]
							
						
					

Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1% - Business Wire

Itching to Expand: Organon to Acquire Dermavant - Law Street Media 


						
															

										Post
									
								Plaque Psoriasis													
						
							
								Dermavant Presents Positive Results from Phase 4 Open-Label Trial of VTAMA® (tapinarof) Cream, 1% for the Treatment of Intertriginous Plaque Psoriasis in Adults at 43rd Annual Fall Clinical Dermatology Conference
							
							
								— Notably, 82.8% of adult patients achieved an intertriginous Physician Global Assessment (iPGA) Score of 0 (clear) or 1 (almost clear) and ≥ 2-grade improvement from baseline at Week 12, demonstrating compelling efficacy. — — Patients experienced a rapid onset of efficacy, with iPGA success occurring, as early as 2 weeks, with a median time […]
							
						
					

Organon to acquire Dermavant in $1.2B deal - NJBIZ

Organon to acquire Dermavant in back-loaded deal - The Pharma Letter

Patient Assistance Program
  
    
  


Organon completes Dermavant Sciences acquisition - Investing.com India

Dermavant names John Darden as new head of marketing - The Pharma Letter


						
															

										Post
									
								Corporate													
						
							
								Dermavant Announces Appointment of Michael Swartzburg as Chief Financial Officer
							
							
								– Over 20 Years of Combined Experience in Global Finance Leadership, Audit, and Advisory Roles in the Biopharmaceutical Industry LONG BEACH, Calif., and BASEL, Switzerland, May 6, 2021—Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, today announced the appointment of Michael Swartzburg as Chief Financial Officer. Mr. Swartzburg […]
							
						
					

Dermavant publishes positive phase 3 data for treatment of plaque psoriasis - PMLiVE

http://www.dermavant.com/

Organon Completes Acquisition of Dermavant - citybiz

Dermavant Announces FDA Acceptance for Filing of New Drug Application (NDA) for Tapinarof Cream for the Treatment of Adults with Plaque Psoriasis - Business Wire

Patients with eczema and healthcare practitioners are in need of dermatological innovation. We’re proud to be on the cusp of introducing a cutting-edge treatment option where few existed before, potentially offering patients and providers a different opportunity for effective care. #SkinDeservesMore #NationalEczemaWeek


						
															

										Post
									
								Atopic Dermatitis													
						
							
								Dermavant to Present Data from Multiple Clinical Trials of VTAMA® (tapinarof) cream, 1% at the 2022 Fall Clinical Dermatology Conference
							
							
								– Five posters will highlight clinical data for VTAMA cream for the treatment of plaque psoriasis in adults and for atopic dermatitis in patients as young as two – LONG BEACH, Calif., and BASEL, Switzerland, Oct. 13, 2022 — Dermavant Sciences, a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, today announced […]
							
						
					

Freshfields advises Roivant in sale of Dermavant to Organon - Freshfields Bruckhaus Deringer

Dermavant to recruit 30 patients in Phase IIa vitiligo trial - Clinical Trials Arena

GSK Sells Psoriasis/Dermatitis Candidate Tapinarof to Dermavant - Genetic Engineering & Biotechnology News

Sponsorships

 Dermavant Completes Patient Enrollment for Two Phase 3 Clinical Trials of Tapinarof for the Treatment of Psoriasis 


						
															

										Post
									
								Corporate													
						
							
								Dermavant Sciences Announces Appointment of Dr. Philip M. Brown as Chief Medical Officer
							
							
								Dr. Brown previously served as Head of Global Pharmaceutical Development at Galderma and has over 25 years of experience leading clinical development programs Dermavant plans to initiate Phase 3 clinical program for tapinarof in first half of 2019 BASEL, Switzerland—Jan. 2, 2019—Dermavant Sciences, a dermatology-focused subsidiary of Roivant Sciences, today announced the appointment of Philip M. […]
							
						
					

Dermavant Appoints Chris Chapman as Chief Commercial Officer - GlobeNewswire

FDA Approves Dermavant’s VTAMA® (tapinarof) cream, 1% for the Treatment of Plaque Psoriasis in Adults: First Topical Novel Chemical Entity Launched for Psoriasis in the U.S. in 25 Years - Business Wire

Dermavant Sciences - ABC NEWS 4

Dermavant shows deepening effects of tapinarof on psoriasis ahead of FDA filing - Fierce Biotech


						
															
										Page
									
													
						
							
								Patents
							
							
															
						
					

FDA approves Roivant drug, the first novel topical plaque psoriasis med in 25 years - MedCity News

MyVTAMA Savings Program

Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA - Business Wire

Organon Completes $1.2B Dermavant Acquisition as FDA Decision on Atopic Dermatitis Indication Nears - Femtech Insider

Dermavant Submits Application to FDA for VTAMA Cream for Atopic Dermatitis Treatment in Adults and Children - Managed Healthcare Executive


						
															
										Page
									
													
						
							
								Clinical Trials
							
							
															
						
					

Dermavant reports positive phase 3 results for Vtama cream in atopic dermatitis - PMLiVE

Dermavant launches first streaming commercial for new psoriasis treatment Vtama - FiercePharma

Itching to go: With an FDA approval, Dermavant joins a busy psoriasis market - BioWorld Online

 Dermavant hires CSO from GlaxoSmithKline, buys in excessive sweating drug 

Organon to Acquire Roivant’s Dermatology Subsidiary for Up to $1.2B - Femtech Insider

Atopic Dermatitis Market to Register Incremental Growth by - GlobeNewswire

#AtopicDermatitis is nothing to be ashamed of! Flare the Dragon is showing off his scales and sharing his story and encouraging others to do the same. 

Have a story about eczema or know someone who does? Visit https://bit.ly/3SNFdRC to learn more.

#WorldAtopicEczemaDay

Growing up with eczema can be challenging for kids and often impacts their self-esteem and relationships. But the experiences aren't all negative. 

See Caleb's story of how growing up with eczema shaped his childhood and sense of self and write one of your own: https://bit.ly/4dl4n1l. 

#SkinDeservesMore


                         For Patients
                         

                           
                             
                               
                               
                             
                           

                           
                             
                               
                               
                             
                           
                         
                       

News & Media

 Roivant appoints NEA partner Torti to oversee its ‘vant’ subsidiaries 

#NEWS: Today, Organon announced completing the acquisition of Dermavant Sciences. This step expands Organon’s dermatology capabilities in the U.S. with an additional treatment option. Read the news: https://bit.ly/4hpOauQ.


						
															

										Post
									
								Atopic Dermatitis													
						
							
								Dermavant Completes Enrollment of Two Phase 3 Clinical Trials of VTAMA® (tapinarof) cream, 1% for the treatment of Atopic Dermatitis in Adults and Children as Young as 2 years old
							
							
								– ADORING 1 and 2 trials evaluating VTAMA cream in atopic dermatitis fully enrolled, with topline data expected from the first study in March 2023 and the second study in May 2023 –  – Dermavant recently published highly favorable results from a pediatric maximal usage (MUPK) study of VTAMA cream in atopic dermatitis (AD) demonstrating […]
							
						
					


						
															
										Page
									
													
						
							
								CME Grant
							
							
															
						
					

At #FallClinical we’re presenting new long-term extension data from our open-label ADORING 3 clinical trial studying our topical therapy in clinical development for adults and children as young as 2 years old with #AtopicDermatitis. These data highlight the potential of our topical therapy to be a safe and long-term treatment option for those who need it most. Read more here: https://bit.ly/3ULDCwL. #SkinDeservesMore


http://www.dermavant.com

Dermavant submits new drug application for tapinarof cream in atopic dermatitis - Healio

 Clinical Catch-Up: May 25-29 

Dermavant hires CSO from GlaxoSmithKline, buys excessive sweating drug - Fierce Biotech


						
															

										Post
									
								Corporate													
						
							
								Dermavant Appoints Chris Chapman as Chief Commercial Officer
							
							
								Over 20 years of leadership experience in the biopharmaceutical industry Former Vice President and General Manager, U.S. Prescription Business for Galderma Former Head of Pfizer’s U.S. Pharmaceutical Contracting and Pricing Organization Dermavant expects Phase 3 data for tapinarof in 2020 LONG BEACH, Calif. and BASEL, Switzerland—Jan. 22, 2020—Dermavant Sciences, a dermatology-focused subsidiary of Roivant Sciences, […]
							
						
					

Dermavant Announces New Positive Pruritus Data for VTAMA®(tapinarof) Cream, 1% in Adults and Children as Young as Two Years Old with Atopic Dermatitis at the EADV Congress 2023 - National Eczema Association


						
															

										Post
									
								Plaque Psoriasis													
						
							
								Dermavant Completes Patient Enrollment for Two Phase 3 Clinical Trials of Tapinarof for the Treatment of Psoriasis
							
							
								Tapinarof is a Potential First-in-Class Psoriasis Treatment with a Novel Mechanism of Action Dermavant Expects to Announce Results from PSOARING 1 and PSOARING 2 in 2H 2020 A Long-Term Safety Study for Tapinarof Continues Enrolling Patients LONG BEACH, Calif. and BASEL, Switzerland, Apr. 2, 2020—Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, today […]
							
						
					

Join us in congratulating our very own CFO, Michael Swartzburg, for being recognized by L.A. Times B2B Publishing as an Honoree at the 2024 CFO Forum & Leadership Awards in the category of Midsize Public Company. We’re grateful for his commitment to our continued success and proud to see his hard work and dedication recognized. Read more about the ceremony: https://bit.ly/3YC4zoB. 


Children with eczema face bullying because of their condition. This Eczema Awareness Month, let's show them the love, respect and support they deserve. Together, we can create a stronger, more compassionate community where everyone feels heard and respected.

#SkinDeservesMore #EczemaAwarenessMonth

Dermavant Sciences has a new home. We are excited to be a part of Organon to help make a better and healthier everyday a reality for patients, families, and communities Follow us at: Organon

Pipeline

FORTUNE Names Dermavant One of the 2021 Best Workplaces in Health Care & Biopharma - Business Wire

Dermavant reports positive long-term results for Vtama cream in atopic dermatitis - PMLiVE

Organon to buy skin therapy developer Dermavant for up to $1.2B - ROI-NJ.com


						
															

										Post
									
								Corporate													
						
							
								Dermavant Sciences Announces Appointment of Cyril Allouche as Chief Financial Officer and Provides Recent Corporate Update
							
							
								Mr. Allouche has over 20 years of combined experience in finance leadership, audit, and advisory roles, most recently serving as Principal Accounting Officer, Head of Finance, and Corporate Controller at Revance Therapeutics Dermavant plans to initiate Phase 3 clinical program for tapinarof in second quarter of 2019 United States Patent and Trademark Office (USPTO) issues […]
							
						
					

Find Your Field Medical Director

Dermavant maps out atopic dermatitis filing after positive Phase III data - Clinical Trials Arena

Dermavant Sciences is thrilled to have joined Organon – a company with international dermatology capabilities and expertise that spans existing dermatology treatments. Stay tuned for updates and follow us at: Organon


						
															

										Post
									
								Plaque Psoriasis													
						
							
								Dermavant to Present New Positive Data from Phase 4, Open Label Trial of VTAMA® (tapinarof) Cream, 1% for Intertriginous Plaque Psoriasis in Adults and Multiple Clinical Trials of VTAMA cream at the 2023 Fall Clinical Dermatology Conference
							
							
								– Six posters will highlight clinical data for VTAMA cream for the treatment of plaque psoriasis in adults and for atopic dermatitis in patients as young as two years old – LONG BEACH, Calif., and BASEL, Switzerland, October 16, 2023 – Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, […]
							
						
					


						
															

										Post
									
								Corporate													
						
							
								Appointment of Jackie Fouse
							
							
								Dermavant Sciences Appoints Dr. Jacqualyn Fouse as Executive Chairman Dr. Fouse recently served as President and COO of Celgene Corp. and a member of Celgene’s Board of Directors Dr. Fouse joins growing network of industry leaders within the Roivant Sciences family of companies BASEL, Switzerland, July 10, 2017 /PRNewswire/ — Dermavant Sciences, a biopharmaceutical company […]
							
						
					

In fresh threat to Incyte's Opzelura, Dermavant's Vtama cream hits goal in eczema phase 3 study - FiercePharma


						
															

										Post
									
								Corporate													
						
							
								Dermavant Sciences Appoints Timothy S. Nelson and Kenneth E. Ludlum to Board of Directors
							
							
								LONDON—May 15, 2019—Dermavant Sciences, a dermatology-focused subsidiary of Roivant Sciences, today announced that Timothy S. Nelson and Kenneth E. Ludlum have been appointed to Dermavant’s Board of Directors. Mr. Nelson served as President and Chief Executive Officer, and member of the Board of Directors, of MAP Pharmaceuticals, Inc. from 2005 until its acquisition by Allergan […]
							
						
					


						
															

										Post
									
								Corporate													
						
							
								Dermavant Announces Changes to Leadership and Board of Directors
							
							
								• Dr. Jackie Fouse to step down as Executive Chair of Dermavant
• Dr. Frank Torti named Chairman of the Board, and Myrtle Potter also joins board of directors
• Dermavant prepares Phase…
							
						
					

Contact Us

Dermavant Sciences

Business:

Drug notes:

About: